Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 M{PLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMECwNlg4KM7:TR?= NUnp[XVQW0GQR1XS
LC-2-ad NYTwdVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDkRldKSzVyPUCuNFAxOzF5IN88US=> NFrJcZlUSU6JRWK=
RL95-2 M4niZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMECwOlY5KM7:TR?= NEPJe25USU6JRWK=
MZ1-PC NW\HWHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG2S|g{UUN3ME2wMlAxODd{OTFOwG0> NHvwT2JUSU6JRWK=
TE-8 M2DY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXoTWM2OD1yLkCwNVE4KM7:TR?= NFrZSI1USU6JRWK=
SW954 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3nd3JKSzVyPUCuNFAyOTlizszN Mn\SV2FPT0WU
TE-11 M2Tkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMECxNlMh|ryP MV7TRW5ITVJ?
PSN1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHsTWM2OD1yLkCwNVMh|ryP NFLs[ndUSU6JRWK=
MOLT-4 NGTZO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXYPJBKSzVyPUCuNFAyPDlizszN NYnvXIZpW0GQR1XS
697 NY\lfXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTkXWNKSzVyPUCuNFAyPSEQvF2= NXm2eFdTW0GQR1XS
ETK-1 M1jhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMECxOVIh|ryP M4K1d3NCVkeHUh?=
TE-10 NEHnToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLt[4tyUUN3ME2wMlAxOTV2IN88US=> MX;TRW5ITVJ?
HUTU-80 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDCTWM2OD1yLkCwNVY5KM7:TR?= MYHTRW5ITVJ?
NTERA-S-cl-D1 NYDwelNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH0[IhKSzVyPUCuNFAzODlizszN MUfTRW5ITVJ?
MFH-ino M1qyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMECyOlgh|ryP NUPySXl{W0GQR1XS
IA-LM NFyzbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMECyPEDPxE1? NUfrSWZEW0GQR1XS
MC116 M3vNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMECyPFkh|ryP M2LIXnNCVkeHUh?=
RKO MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMECyPVgh|ryP NVXBXZRjW0GQR1XS
MRK-nu-1 NX73doFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLHXXhnUUN3ME2wMlAxOjl7IN88US=> NX3vZnVkW0GQR1XS
VA-ES-BJ NVzWd|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmWmlEPTB;MD6wNFMh|ryP NF7KNIZUSU6JRWK=
KALS-1 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnJUoV7UUN3ME2wMlAxOzB6IN88US=> MVnTRW5ITVJ?
BB30-HNC MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMECzNVQh|ryP MoXkV2FPT0WU
ACN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMECzNVYh|ryP M1z1dXNCVkeHUh?=
TE-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXYTWM2OD1yLkCwN|I3KM7:TR?= MV7TRW5ITVJ?
SIG-M5 NUjCTZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMECzNlch|ryP NIXVUHpUSU6JRWK=
no-10 M2DVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLxdGNGUUN3ME2wMlAxOzZ{IN88US=> MYXTRW5ITVJ?
EW-1 NWf1NZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fH[2lEPTB;MD6wNFM4OSEQvF2= M2XrO3NCVkeHUh?=
SK-LMS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrGcpFtUUN3ME2wMlAxPDBzIN88US=> MYHTRW5ITVJ?
GT3TKB MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foRWlEPTB;MD6wNFQ{PCEQvF2= NX;HT2pyW0GQR1XS
ES4 NWTzfVlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr1Vo9LUUN3ME2wMlAxPDR7IN88US=> MYHTRW5ITVJ?
IMR-5 NGjUXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\GfWNKSzVyPUCuNFA1PSEQvF2= NH33fGZUSU6JRWK=
NCI-H1648 NIDNXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTsRVVKSzVyPUCuNFA1PjlizszN MWjTRW5ITVJ?
MV-4-11 M1H5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrlUFBVUUN3ME2wMlAxPDd3IN88US=> M1LFfnNCVkeHUh?=
SK-UT-1 NXr5OFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7vSnFKSzVyPUCuNFA1QCEQvF2= MmrjV2FPT0WU
NB13 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPkUI1RUUN3ME2wMlAxPDlzIN88US=> MV7TRW5ITVJ?
DJM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojmTWM2OD1yLkCwOVMh|ryP MkTyV2FPT0WU
ES8 NXrLTXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC1N|gh|ryP NFzz[HNUSU6JRWK=
TE-6 NI\EcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEC1O{DPxE1? MkXyV2FPT0WU
KS-1 NEn0VW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDHTWM2OD1yLkCwOVgzKM7:TR?= MWDTRW5ITVJ?
TE-1 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnyTWM2OD1yLkCwOlA3KM7:TR?= MVjTRW5ITVJ?
ATN-1 NVvRfoV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr0UmdKSzVyPUCuNFA3ODlizszN M2m1cXNCVkeHUh?=
A4-Fuk MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3izPWlEPTB;MD6wNFYyOSEQvF2= MoTJV2FPT0WU
ALL-PO NELxOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7xdVRKSzVyPUCuNFA3OyEQvF2= NEDVfZBUSU6JRWK=
BE-13 M1jadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzqPXYxUUN3ME2wMlAxPjN4IN88US=> NUX3cHdVW0GQR1XS
KM12 NYLtb442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fx[GlEPTB;MD6wNFY{PyEQvF2= NF2wdlZUSU6JRWK=
NOS-1 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPHR3FKSzVyPUCuNFA3PSEQvF2= M{jYNnNCVkeHUh?=
SW962 M{D1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnPbY1KSzVyPUCuNFA3PjJizszN MlPlV2FPT0WU
OCUB-M M4HUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0TWM2OD1yLkCwOlYzKM7:TR?= M4DWU3NCVkeHUh?=
NCI-H510A M2XnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPNTWM2OD1yLkCwOlY2KM7:TR?= NGXDS3lUSU6JRWK=
EW-16 M4KzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnLWnZKSzVyPUCuNFA3QTRizszN MlzHV2FPT0WU
KGN NEfxVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\VZ|ZKSzVyPUCuNFA4OTJizszN MkD0V2FPT0WU
LS-411N M1e1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEC3NVch|ryP MXTTRW5ITVJ?
Becker M4j3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJTWM2OD1yLkCwO|Ih|ryP MmKxV2FPT0WU
HC-1 NFvYWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGzVFRKSzVyPUCuNFA4OjFizszN NXXVVmp6W0GQR1XS
CESS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjOdoM{UUN3ME2wMlAxPzN5IN88US=> NF75WYRUSU6JRWK=
KURAMOCHI MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC2Xo1KSzVyPUCuNFA4PDhizszN NITjPG1USU6JRWK=
TGBC24TKB NVrUcpI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHrXlVHUUN3ME2wMlAxPzV{IN88US=> MlK3V2FPT0WU
SW982 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEC3OlYh|ryP NFnuOGxUSU6JRWK=
HCE-4 NITnT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEC3Olch|ryP M4GyWHNCVkeHUh?=
LOUCY M2H5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEC3O|Uh|ryP M1;Q[3NCVkeHUh?=
8-MG-BA NXnZUZhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1yLkCwO|k3KM7:TR?= MYnTRW5ITVJ?
HT-144 NWjXdJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml62TWM2OD1yLkCwPEDPxE1? NVrKTGFvW0GQR1XS
LXF-289 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHJbXhlUUN3ME2wMlAxQDF6IN88US=> NEfrPVJUSU6JRWK=
RS4-11 NVniSolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEC4N|Yh|ryP NXnReY1OW0GQR1XS
DEL NV7aVVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\qT5pKSzVyPUCuNFA5PDVizszN NIDGVXRUSU6JRWK=
OCI-AML2 M4PU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XGfGlEPTB;MD6wNFg2OiEQvF2= NEP2WJpUSU6JRWK=
CCRF-CEM NG\5WIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLwTWM2OD1yLkCwPFcyKM7:TR?= M3;WVXNCVkeHUh?=
A388 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEC4O|Qh|ryP M2TDSnNCVkeHUh?=
KNS-42 NFH3fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DT[WlEPTB;MD6wNFg6OSEQvF2= MmTQV2FPT0WU
OVCAR-4 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfhUZRkUUN3ME2wMlAxQTB2IN88US=> MYDTRW5ITVJ?
NCI-H1355 M4DlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEC5NVQh|ryP NIHKN5JUSU6JRWK=
BL-70 M{[xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf4WGp1UUN3ME2wMlAxQTNizszN NFvtc4tUSU6JRWK=
BL-41 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPTTWM2OD1yLkCwPVM1KM7:TR?= MWDTRW5ITVJ?
A101D NX3hfYtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITPPVdKSzVyPUCuNFA6PiEQvF2= NEDRS25USU6JRWK=
HL-60 M2DjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEC5OlYh|ryP MlnYV2FPT0WU
COR-L279 NXjTeGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnRWYt5UUN3ME2wMlAxQTl7IN88US=> MnyzV2FPT0WU
NCI-SNU-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKWIhUUUN3ME2wMlAyODB6IN88US=> Mn;PV2FPT0WU
Calu-6 NHjBPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvxfGtEUUN3ME2wMlAyODF{IN88US=> M{fPSHNCVkeHUh?=
SR NYLRbVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorXTWM2OD1yLkCxNFI3KM7:TR?= M4nRNnNCVkeHUh?=
QIMR-WIL NVnt[lh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfwTWM2OD1yLkCxNFM{KM7:TR?= NEnsfZlUSU6JRWK=
LB647-SCLC NIruTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLhTWM2OD1yLkCxNFUyKM7:TR?= NYrNV3pGW0GQR1XS
RPMI-8226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M370bmlEPTB;MD6wNVExOiEQvF2= NYrKeGRRW0GQR1XS
SK-PN-DW NXj6Rll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G0fmlEPTB;MD6wNVEyOiEQvF2= NULjRZRQW0GQR1XS
SF268 NUn4U|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD1yLkCxNVUyKM7:TR?= M2XtfXNCVkeHUh?=
HD-MY-Z NF3ITHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEGxOlMh|ryP M3XJWHNCVkeHUh?=
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoftTWM2OD1yLkCxNlA{KM7:TR?= MYPTRW5ITVJ?
SCC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnfItHUUN3ME2wMlAyOjB2IN88US=> MXPTRW5ITVJ?
ST486 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEGyNFQh|ryP MljrV2FPT0WU
NALM-6 NEnndZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljwTWM2OD1yLkCxNlE1KM7:TR?= Ml75V2FPT0WU
NCI-H1436 NYK3ZWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjpTWM2OD1yLkCxNlMyKM7:TR?= NF7t[JdUSU6JRWK=
KE-37 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEGyN|Qh|ryP M3;qfXNCVkeHUh?=
RPMI-8402 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnmTWM2OD1yLkCxNlU3KM7:TR?= M{LsVnNCVkeHUh?=
RXF393 M4DaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzaXZo1UUN3ME2wMlAyOjV5IN88US=> M{SzS3NCVkeHUh?=
KARPAS-45 NVnqWJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H3OGlEPTB;MD6wNVI4KM7:TR?= NVi0doxuW0GQR1XS
HOP-62 NVHtU2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G5RmlEPTB;MD6wNVI4PiEQvF2= M2DwTHNCVkeHUh?=
ES1 NGDNSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPMOHpKSzVyPUCuNFEzQDhizszN Mk\RV2FPT0WU
L-363 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEGzOVEh|ryP MWHTRW5ITVJ?
GI-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vPO2lEPTB;MD6wNVM4OyEQvF2= NVnafXhVW0GQR1XS
CTV-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[ydWZKSzVyPUCuNFE1PzhizszN M1zxdnNCVkeHUh?=
TE-5 NX\mPWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftU2lEPTB;MD6wNVQ6PiEQvF2= NUnScHhtW0GQR1XS
SNU-C2B NHrJUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rTdWlEPTB;MD6wNVQ6PiEQvF2= Mly1V2FPT0WU
K-562 NWfRfItiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofkTWM2OD1yLkCxOVE3KM7:TR?= MVvTRW5ITVJ?
SNB75 M1y2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHZTWM2OD1yLkCxOVQh|ryP MULTRW5ITVJ?
MOLT-13 M2HrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEG2N|ch|ryP MXXTRW5ITVJ?
LS-123 NFf2PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDhTWM2OD1yLkCxOlY1KM7:TR?= NV\6XJJSW0GQR1XS
NCI-SNU-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULMSlhnUUN3ME2wMlAyPzBzIN88US=> NYrGVnd6W0GQR1XS
Daudi M2LDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzUGlEPTB;MD6wNVcxQCEQvF2= MX\TRW5ITVJ?
A253 NF\0dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEG3N|gh|ryP M3:wO3NCVkeHUh?=
TGBC1TKB NICxUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEG3OVIh|ryP NVLDZmR5W0GQR1XS
SJSA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfnTWM2OD1yLkCxO|Y4KM7:TR?= MVvTRW5ITVJ?
NCCIT M1m3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXPTWM2OD1yLkCxO|Y6KM7:TR?= NGK2ZllUSU6JRWK=
NCI-H69 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL6R3pKSzVyPUCuNFE4PzhizszN MX3TRW5ITVJ?
SH-4 M1\i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKyRoZmUUN3ME2wMlAyQDl3IN88US=> MnTqV2FPT0WU
HCC1187 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pTWM2OD1yLkCxPVI1KM7:TR?= NFPPTpRUSU6JRWK=
HCC1599 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEKwNkDPxE1? M2HEbXNCVkeHUh?=
ONS-76 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvtTWM2OD1yLkCyNFM3KM7:TR?= NEDTW4RUSU6JRWK=
KU812 M321cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEKwN|kh|ryP NHnvRWJUSU6JRWK=
ML-2 M2DaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm3TWM2OD1yLkCyNFQ4KM7:TR?= MoP6V2FPT0WU
HCE-T MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEKwPVIh|ryP NUnlWmpSW0GQR1XS
NCI-H446 NUTDdnV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3XTWM2OD1yLkCyNVEzKM7:TR?= NWDrOHhLW0GQR1XS
RPMI-6666 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWyVYNKSzVyPUCuNFIyPDlizszN MVHTRW5ITVJ?
MOLT-16 NVT1VXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;HWHhKSzVyPUCuNFIyPTNizszN NYPBXVhLW0GQR1XS
JiyoyeP-2003 M3zZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4niSmlEPTB;MD6wNlE4PiEQvF2= MkTvV2FPT0WU
MHH-PREB-1 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonETWM2OD1yLkCyNVkyKM7:TR?= NEXON2hUSU6JRWK=
MC-CAR MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorNTWM2OD1yLkCyN|I3KM7:TR?= M{D5c3NCVkeHUh?=
BC-3 NFyzZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XCOGlEPTB;MD6wNlM1PCEQvF2= NHnIR|lUSU6JRWK=
KINGS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oeoVWUUN3ME2wMlAzOzV3IN88US=> MWnTRW5ITVJ?
PF-382 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml31TWM2OD1yLkCyN|c5KM7:TR?= NWDqdYtYW0GQR1XS
J-RT3-T3-5 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4R4dKSzVyPUCuNFI{QDNizszN M2nqdnNCVkeHUh?=
SF539 NIjWdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXaTWM2OD1yLkCyOFAyKM7:TR?= MmDsV2FPT0WU
LB831-BLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTVd4VzUUN3ME2wMlAzPDh3IN88US=> M1;qPXNCVkeHUh?=
DMS-114 NIj0cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEK1NFIh|ryP NEDtOW9USU6JRWK=
LB1047-RCC NYnqTXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3wdHBKSzVyPUCuNFI2OSEQvF2= NWG0S3dxW0GQR1XS
LB771-HNC M2e3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrBd|NKSzVyPUCuNFI2OzRizszN NInwb|FUSU6JRWK=
BB65-RCC NWS3UYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rGTmlEPTB;MD6wNlU{PCEQvF2= M3i3eHNCVkeHUh?=
BV-173 NG\xfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPTWM2OD1yLkCyOVU1KM7:TR?= M1TweXNCVkeHUh?=
ARH-77 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XVVGlEPTB;MD6wNlYxOSEQvF2= NIjqNXVUSU6JRWK=
IST-MEL1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfLTWM2OD1yLkCyOlI{KM7:TR?= M174TnNCVkeHUh?=
NB1 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ETWM2OD1yLkCyOlg4KM7:TR?= M1TQ[3NCVkeHUh?=
EoL-1-cell MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEK2PFgh|ryP M2PDcnNCVkeHUh?=
KY821 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzhZpBjUUN3ME2wMlAzPjl5IN88US=> M3jYOnNCVkeHUh?=
CMK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTFTWM2OD1yLkCyO|M1KM7:TR?= NWHYbmV1W0GQR1XS
NCI-H2126 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K4N2lEPTB;MD6wNlc3QCEQvF2= MmL3V2FPT0WU
NCI-H526 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsTWM2OD1yLkCyPFkyKM7:TR?= MXvTRW5ITVJ?
COLO-684 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fC[WlEPTB;MD6wNlkxQCEQvF2= NH;CZXJUSU6JRWK=
NCI-H747 NV7SN5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q3fWlEPTB;MD6wNlk{OyEQvF2= M{f5b3NCVkeHUh?=
JAR NIrjOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofETWM2OD1yLkCyPVQ3KM7:TR?= NFnrRZFUSU6JRWK=
MEG-01 NEf5cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPTTWM2OD1yLkCyPVc5KM7:TR?= NGnRTVlUSU6JRWK=
MONO-MAC-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[yTWM2OD1yLkCzNFI{KM7:TR?= MlXpV2FPT0WU
IST-SL1 NVL6RnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\xW2lEPTB;MD6wN|A1OiEQvF2= M2jYeXNCVkeHUh?=
CPC-N NH7PSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lTmlEPTB;MD6wN|A4QSEQvF2= M2Gwd3NCVkeHUh?=
NCI-H1963 NUn3TlM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEOxN|Eh|ryP M4Djd3NCVkeHUh?=
K052 MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHpbVk2UUN3ME2wMlA{OjR5IN88US=> MYPTRW5ITVJ?
KM-H2 M{\OSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGyTWM2OD1yLkCzN|A4KM7:TR?= Ml[4V2FPT0WU
TE-12 M1P4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEOzNFkh|ryP MXPTRW5ITVJ?
TK10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEOzOVYh|ryP MnrRV2FPT0WU
NMC-G1 NHWx[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrScY9{UUN3ME2wMlA{PDV{IN88US=> MnzXV2FPT0WU
no-11 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPmVG9KSzVyPUCuNFM1PzhizszN NV\3PWI3W0GQR1XS
NCI-H524 NESyZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfoXnpKSzVyPUCuNFM2OjlizszN MnXwV2FPT0WU
MHH-CALL-2 M3T0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ryTmlEPTB;MD6wN|U3OiEQvF2= MoD4V2FPT0WU
GB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEO2JO69VQ>? M4rwSXNCVkeHUh?=
OPM-2 NVj0UJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTsTWM2OD1yLkCzOlc{KM7:TR?= M3Tse3NCVkeHUh?=
RH-1 M4jWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L0[WlEPTB;MD6wN|gyQSEQvF2= NUH1WHN{W0GQR1XS
NCI-H64 NI\vclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XNdGlEPTB;MD6wN|g2PyEQvF2= NWDMbGpGW0GQR1XS
EVSA-T NH;wZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonpTWM2OD1yLkCzPVI{KM7:TR?= MVfTRW5ITVJ?
KARPAS-299 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vFeWlEPTB;MD6wN|k5KM7:TR?= Ml7KV2FPT0WU
MZ7-mel NWnRZoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD1yLkC0NFQh|ryP M4jtOXNCVkeHUh?=
LB373-MEL-D MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qxbmlEPTB;MD6wOFExPSEQvF2= NEm2fpBUSU6JRWK=
HEL Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjZTWM2OD1yLkC0NVQh|ryP NHPTN3pUSU6JRWK=
SW872 NXnSdoRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMESyNUDPxE1? NXzINYhNW0GQR1XS
DU-4475 NE[2ZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnHTWM2OD1yLkC0NlQ1KM7:TR?= MWrTRW5ITVJ?
IST-SL2 NUfIN5VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21TWM2OD1yLkC0Nlc2KM7:TR?= NX65bmVGW0GQR1XS
NCI-H82 M2TtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMESzNFch|ryP Mki4V2FPT0WU
LC4-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXDNmw5UUN3ME2wMlA1OzVzIN88US=> MV\TRW5ITVJ?
HDLM-2 NWTucndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rLXWlEPTB;MD6wOFM6OiEQvF2= M1XyS3NCVkeHUh?=
MMAC-SF MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr1UIxOUUN3ME2wMlA1PTN2IN88US=> MlLTV2FPT0WU
L-540 NF;Ld41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfqWJdKSzVyPUCuNFQ3OzlizszN NFzFV4tUSU6JRWK=
MZ2-MEL M2qyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj0TWM2OD1yLkC0O|QzKM7:TR?= M{LoPHNCVkeHUh?=
LU-134-A MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVztRm9sUUN3ME2wMlA1Pzd|IN88US=> NFLlUWRUSU6JRWK=
UACC-257 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2OD1yLkC0PFQ6KM7:TR?= MX7TRW5ITVJ?
NCI-H1581 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMES5OVMh|ryP NVPqOo9KW0GQR1XS
NB17 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ZPWtmUUN3ME2wMlA1QTd7IN88US=> M3;1dnNCVkeHUh?=
SBC-1 NF\wc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HwNmlEPTB;MD6wOVA1OiEQvF2= M4XWZXNCVkeHUh?=
TALL-1 NGPsW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj5bVNXUUN3ME2wMlA2ODR3IN88US=> M2q1fXNCVkeHUh?=
NCI-H1304 M2PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u5VWlEPTB;MD6wOVIxQCEQvF2= NFq0VotUSU6JRWK=
NEC8 NUTRbHhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTRS|NKSzVyPUCuNFUzQDZizszN MnjKV2FPT0WU
CAL-148 M4LYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjPTWM2OD1yLkC1OFM6KM7:TR?= NIThbYRUSU6JRWK=
CGTH-W-1 NV3LXIdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV23PZA5UUN3ME2wMlA2PDR7IN88US=> MnPFV2FPT0WU
NCI-H889 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jVfGlEPTB;MD6wOVU6OiEQvF2= NFrWXWNUSU6JRWK=
GR-ST NILRcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\YTWM2OD1yLkC1OlIyKM7:TR?= MWTTRW5ITVJ?
KARPAS-422 M3K1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSze4hKSzVyPUCuNFU3PSEQvF2= NHi4bIdUSU6JRWK=
RPMI-8866 NF7Q[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEW3NVIh|ryP MV\TRW5ITVJ?
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[1ZmlEPTB;MD6wOVg5PCEQvF2= MofXV2FPT0WU
COR-L88 NX;WZlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULITGZQUUN3ME2wMlA2QTJ5IN88US=> MUnTRW5ITVJ?
LU-139 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq1V2dKSzVyPUCuNFU6QDZizszN MkH4V2FPT0WU
SF126 NVXxVm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwME[xN|Mh|ryP MUjTRW5ITVJ?
NCI-H1882 NVXMdWV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlWVZuUUN3ME2wMlA3PDJ2IN88US=> NE\LdpVUSU6JRWK=
EW-24 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ZbGlEPTB;MD6wOlQ5OyEQvF2= NF\yVHpUSU6JRWK=
CP67-MEL M4\ZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXaV2R[UUN3ME2wMlA3QDFizszN M2PDbXNCVkeHUh?=
DG-75 NVz3VY42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjjN3BKSzVyPUCuNFY5QTlizszN NX2wUHZqW0GQR1XS
LOXIMVI M37JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H4XWlEPTB;MD6wO|AzQCEQvF2= M2nq[XNCVkeHUh?=
HH NVqyWYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLSTWM2OD1yLkC3NVU4KM7:TR?= NWPKdHliW0GQR1XS
K5 NWT0XIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTFOHp7UUN3ME2wMlA4OjJ4IN88US=> MWDTRW5ITVJ?
EC-GI-10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEeyOVch|ryP M2jtPXNCVkeHUh?=
SK-N-DZ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXMPVFKSzVyPUCuNFc{ODdizszN MmrBV2FPT0WU
A3-KAW M1u0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEezOVEh|ryP NYjNXJZWW0GQR1XS
MLMA NUnwUGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvhTWM2OD1yLkC3OFY2KM7:TR?= M16zUnNCVkeHUh?=
LB996-RCC NEnyNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHwRpJKSzVyPUCuNFc4ODdizszN NFr6fWxUSU6JRWK=
OS-RC-2 NGK1[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHMTWM2OD1yLkC3O|Q5KM7:TR?= Mlz2V2FPT0WU
CTB-1 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEe4NUDPxE1? NGe1TopUSU6JRWK=
IST-MES1 NHjvPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPETWM2OD1yLkC3PVEzKM7:TR?= NYPI[XRUW0GQR1XS
LS-1034 NWrONow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4TWM2OD1yLkC4NFM2KM7:TR?= NVG2S5BnW0GQR1XS
HT NEjJSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEiwPFYh|ryP NHnTXotUSU6JRWK=
NCI-H2141 NGfoS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\nW5M6UUN3ME2wMlA5OSEQvF2= M3j3WHNCVkeHUh?=
LB2518-MEL M3KxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGTWM2OD1yLkC4NVQyKM7:TR?= M1KzSnNCVkeHUh?=
GI-ME-N NYDPUJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvJeFZIUUN3ME2wMlA5PDV{IN88US=> M3jF[3NCVkeHUh?=
TGW NYXsZ5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTnUJlKSzVyPUCuNFg3ODdizszN MUfTRW5ITVJ?
SK-NEP-1 NFHjSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj4emJIUUN3ME2wMlA5PjRzIN88US=> M1fF[HNCVkeHUh?=
NOMO-1 NYfLUZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;zZmVPUUN3ME2wMlA6Ojd3IN88US=> NIH2eItUSU6JRWK=
ES6 M3H6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC0UWRKSzVyPUCuNFk2QDlizszN Mkm5V2FPT0WU
NCI-H209 M4S4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLhdpNKSzVyPUCuNFk4QDZizszN NGW5emlUSU6JRWK=
GAK MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrGcFBbUUN3ME2wMlExOTZizszN MX3TRW5ITVJ?
BC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTaTWM2OD1yLkGwN|YyKM7:TR?= NXqwTHgxW0GQR1XS
KLE MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;6[FN5UUN3ME2wMlExPDR|IN88US=> MUTTRW5ITVJ?
EW-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMUC5PEDPxE1? NGX5Z4xUSU6JRWK=
NKM-1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMUGxJO69VQ>? M4\pOXNCVkeHUh?=
D-336MG NVz1[5NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezb4dKSzVyPUCuNVEzPDRizszN MkXwV2FPT0WU
NB69 NU\CSG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2x[G5KSzVyPUCuNVE{ODFizszN NGTE[pdUSU6JRWK=
D-263MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjHOHdiUUN3ME2wMlEyPzF{IN88US=> NYTNR4l2W0GQR1XS
KP-N-YS NEDFXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlryTWM2OD1yLkGyNlkyKM7:TR?= MmK4V2FPT0WU
NCI-H1155 M1TFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUK1OVgh|ryP NVzYSXJKW0GQR1XS
BOKU NYrqSYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUK1O|kh|ryP MVnTRW5ITVJ?
LAMA-84 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;CSWlEPTB;MD6xNlk6KM7:TR?= NGrWN|dUSU6JRWK=
Raji M3rvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHvO3NKSzVyPUCuNVMyOTdizszN NGX6fopUSU6JRWK=
LU-65 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjaZY9sUUN3ME2wMlE{OzB5IN88US=> MVTTRW5ITVJ?
NCI-H187 M2TzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrDSXlKSzVyPUCuNVM6OjRizszN M{XVdnNCVkeHUh?=
GCIY MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMUS5NFEh|ryP NX;IN4toW0GQR1XS
NCI-H2107 NWHjXZJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K4dmlEPTB;MD6xOVA5KM7:TR?= M{LkXnNCVkeHUh?=
NCI-H1522 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfrNmtKSzVyPUCuNVUzPjZizszN M2[yeHNCVkeHUh?=
NB6 NHPvbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z4V2lEPTB;MD6xOVYzOyEQvF2= M3fuTnNCVkeHUh?=
EM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HjdmlEPTB;MD6xOVcxPiEQvF2= MlzWV2FPT0WU
HCC2218 NHnJSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzlcGJFUUN3ME2wMlE2QThizszN MnnmV2FPT0WU
NCI-H748 NIOyfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\vcmlEPTB;MD6xOlM4PiEQvF2= MV;TRW5ITVJ?
MS-1 NWfhO2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1yLkG2OVM4KM7:TR?= NVHvdZlzW0GQR1XS
NB5 M3\IXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMU[1PVch|ryP MWPTRW5ITVJ?
OMC-1 NHv0NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSycGNKSzVyPUCuNVY3QDhizszN M4fvSXNCVkeHUh?=
NCI-H345 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XGd2lEPTB;MD6xOlkzQCEQvF2= NVn1VlQzW0GQR1XS
L-428 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjHPFBKSzVyPUCuNVY6PDVizszN MoSyV2FPT0WU
SCH M3jQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\6TWM2OD1yLkG4Olg2KM7:TR?= MkniV2FPT0WU
NCI-H1417 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;rXWlEPTB;MD6xPVIzPyEQvF2= NIrTc5VUSU6JRWK=
COLO-320-HSR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD1yLkG5OVMzKM7:TR?= MYPTRW5ITVJ?
BT-474 NIPwfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMkC4PVIh|ryP NUDyR4ZVW0GQR1XS
GDM-1 NV\ybmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1yLkKxPVcyKM7:TR?= MVrTRW5ITVJ?
NCI-H2196 NEDFTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jTUWlEPTB;MD6yNlI{PSEQvF2= MX\TRW5ITVJ?
KP-N-RT-BM-1 NF\QZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HIdmlEPTB;MD6yNlM1QSEQvF2= NEDWWXZUSU6JRWK=
KNS-81-FD M4rCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTvfmE4UUN3ME2wMlIzQTV6IN88US=> MYrTRW5ITVJ?
COLO-668 NFjtR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorKTWM2OD1yLkKzOlc2KM7:TR?= MVvTRW5ITVJ?
C2BBe1 NXPnXVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HTXGlEPTB;MD6yOlc1PyEQvF2= M2PSUHNCVkeHUh?=
Ramos-2G6-4C10 NIH2VJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDp[m5KSzVyPUCuNlY6PTRizszN MUTTRW5ITVJ?
CAS-1 NGHMUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMkewPVYh|ryP MW\TRW5ITVJ?
GOTO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\0PIxxUUN3ME2wMlI4QDl2IN88US=> MYLTRW5ITVJ?
LP-1 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK3TWM2OD1yLkK4NFU4KM7:TR?= NGTOVHlUSU6JRWK=
NCI-SNU-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3KbXhKSzVyPUCuNlk1OjJizszN M2TT[HNCVkeHUh?=
EB-3 M3H2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMkm5O|kh|ryP MmHKV2FPT0WU
MHH-NB-11 NFH5dmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XQXWlEPTB;MD6zNFQxOiEQvF2= MXfTRW5ITVJ?
SK-N-FI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHSZW9KSzVyPUCuN|E3QTJizszN NX:4b5l7W0GQR1XS
HCC2157 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e5XmlEPTB;MD6zN|kyOyEQvF2= M{nGXnNCVkeHUh?=
SIMA NHPi[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfGU2Y2UUN3ME2wMlM1PThzIN88US=> NGLFZ4xUSU6JRWK=
MDA-MB-134-VI NULHXGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3G[IpVUUN3ME2wMlM3QTJ6IN88US=> M1\oVXNCVkeHUh?=
NCI-H1694 NX\lO2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK3TWM2OD1yLkO3JO69VQ>? NXqyRWpGW0GQR1XS
EHEB M4ixXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPBTWM2OD1yLkO5NFg2KM7:TR?= MYjTRW5ITVJ?
U-266 M{jDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwM{m4OFYh|ryP NFO2eZpUSU6JRWK=
LC-1F Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe0TmtKSzVyPUCuOFM4PjVizszN MV\TRW5ITVJ?
SHP-77 M32xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP5SolKSzVyPUCuOFc5PTVizszN NXOxTlM5W0GQR1XS
LS-513 NIDSfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLUe2tSUUN3ME2wMlQ6OzB5IN88US=> MnjmV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine sulfate

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ